Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder (FGID) characterized by chronic or recurrent gastrointestinal symptoms without organic changes, and it is also a common disorder of gut–brain interaction (DGBIs).. The symptoms of IBS not only affect the quality of life for individual patients but also place a significant burden on global healthcare systems. The lack of established and universally applicable biomarkers for IBS, along with the substantial variability in symptoms and progression, presents challenges in developing effective clinical treatments. In recent years, preclinical and clinical studies have linked the pathogenesis of IBS to alterations in the composition and function of the intestinal microbiota. Within the complex microbial community of the gut, intricate metabolic and spatial interactions occur among its members and between microbes and their hosts. Amid the multifaceted pathophysiology of IBS, the role of intestinal microenvironment factors in symptom development has become more apparent. This review aims to delve into the changes in the composition and structure of the gut microbiome in individuals with IBS. It explores how diet-mediated alterations in intestinal microbes and their byproducts play a role in regulating the pathogenesis of IBS by influencing the “brain-gut” axis, intestinal barrier function, immune responses, and more. By doing so, this review seeks to lay a theoretical foundation for advancing the development of clinical therapeutics for IBS.

Stephaniae Tetrandrae Radix (STR) is a commonly used herb with a history of thousands of years. Accumulating evidence shows the therapeutic effect on breast cancer (BC) of STR. Here, we aimed to elucidate the active components and mechanisms of STR against BC. The active components and targets were retrieved and screened from the corresponding databases. A target protein–protein interaction (PPI) network was built and Ingenuity Pathway Analysis (IPA) used to analyze and screen key targets and pathways. Subsequently, molecular docking was performed to visualize the patterns of interactions between components and targets. Finally, the main active components of STR in treating BC were confirmed by in vitro experiments, and 34 common targets were obtained. The PPI network and IPA showed that the key targets were TP53, JUN, CASP3, and so on. Additionally, signaling pathways were enriched. Docking verified that the active components have good binding potential with the key targets, especially tetrandrine (Tet) and fangchinoline (Fang). In vitro studies confirmed that they significantly inhibited the viability of MDA-MB-231 cells and increased LDH leakage rate compared to MCF-10A cells. STR participates in many cell processes and regulate multiple targets, thereby playing an anti-breast cancer role. Tet and Fang may be the main active components.